Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after surgery. It enrolled 709 patients, assessing disease-free survival and overall survival as primary end points.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

Now Viewing

EP: 3.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

EP: 4.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

EP: 5.Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

EP: 6.Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

EP: 7.Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

EP: 8.Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

EP: 9.Adjuvant ICI for High-Risk MIUC: Patient Counseling

EP: 10.Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Video content above is prompted by the following:

• Please provide an overview of the CheckMate 274 clinical trial (eg, design and population enrolled).

Recent Videos

Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Adjuvant ICI for High-Risk MIUC: Patient Counseling

Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

MIUC: Risk of Recurrence After Radical Cystectomy